Marinus Pharmaceuticals — Technical Presentation (December 2018)
13 slides from Marinus Pharmaceuticals's technical presentation, Dec 10, 2018
Slide 1: Safe Harbor Statement
Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private
Slide 2: Summary of Top-Line Results
Ganaxolone IV was fast acting, robust and durable Effect seen at 48 hours was durable through Day 34 >5-point reduction in HAM-D17 compared to PBO starting at 48 hours Established a dose response Ganaxolone oral - robust & durable signal Supports IV to oral administration in future studies Summary o
Slide 3: PPD Commercial Opportunity Overview
PPD Commercial Opportunity Overview Substantial Market Opportunity ~550K PPD patients per year in U.S.* High Degree of Unmet Need No approved treatment for PPD currently Significant clinical limitations to SSRIs for treatment of PPD Minimal MOA innovations in last 20+ years in field of depression GN
Slide 4: Ganaxolone Exhibits a Differentiated MOA Over Standard of Care in PPD
Ganaxolone (GNX) Exhibits a Differentiated MOA Over Standard of Care in PPD Ganaxolone is a positive allosteric modulator of synaptic and extrasynaptic GABAA-R Ganaxolone targets unique binding sites that are not susceptible to tolerance build up GNX is a neurosteroid that targets the GABAA receptor
Slide 5: Magnolia Study - Trial Design
Magnolia Study - Trial Design Study Overview Double-blind, placebo-controlled Multiple US sites; 1:1 randomization Multi-cohort, ascending-dose 3 dose regimens studied Objective: Evaluate safety, tolerability, PK & efficacy of ganaxolone IV in women with PPD Ganaxolone IV - 60hr Placebo IV – 60hr N=
Slide 6: Clinically Meaningful Early Response Seen with Ganaxolone IV @ 48-hours
Clinically Meaningful Early Response Seen with Ganaxolone IV @ 48-hours Ganaxolone Median dose 48-Hours 60-Hours 34 Days 60 µg/kg/h (n=8) -9.6 -12.0 -8.4 90 µg/kg/h (n=12) -13.5 -13.4 -17.7 140 µg/kg/h (n=10) -15.1 -16.9 -15.7 Placebo (n=28) -9.5 -12.7 -11.6 Mean HAM-D17 Change from Baseline Ganaxol
Slide 7: Ganaxolone's Early Response Results in a 50% Remission of PPD One Month After Treatment
Ganaxolone’s Early Response Results in a 50% Remission of PPD One Month After Treatment Responders Remitters 60 hr Day 34 0 20 40 60 80 100 % R e s p o n d e r ( ³ 5 0 % H A M - D 1 7 R e d u c t i o n f r o m B a s e l i n e ) Placebo (n=28) GNX 140 m g/kg/hr (n=10) Study Day 48% 67% 75% 48% 60 hr
Slide 8: Attractive Safety Profile
Attractive Safety Profile Ganaxolone was safe and well-tolerated Most common reported AEs were sedation and dizziness No SAEs, no discontinuations due to a TRAE Consistent with prior studies, no reports of syncope or loss of consciousness Clean safety profile supports our vision for out-patient or i
Slide 9: Amaryllis Study – Ganaxolone Oral
Amaryllis Study – Ganaxolone Oral Study Design: Evaluate safety, tolerability, PK and efficacy of oral ganaxolone in women with PPD HAM-D17 score of > 20 but < 26 Ascending dose regimens with oral ganaxolone Efficacy endpoint - change from baseline in HAM-D17 Interim Data: n=18; 4 weeks of dosing Me
Slide 10: PPD Program – Next Steps
Continuing to enroll patients in part 2 Exploring shorter IV infusion followed by oral Top-line data 1H ‘19 Continuing to enroll patients Optimizing dose Top-line data 1H ‘19 PPD Program – Next Steps
Slide 11: Conclusions
Conclusions Ganaxolone IV 140 g/kg/hr demonstrated rapid onset of antidepressant action Clinically meaningful improvement of 5.6 and 4.2 HAM-D17 points over placebo at 48 hrs and 60 hrs, respectively. GNX was safe and well-tolerated No SAEs or discontinuations due to TRAEs No syncope or loss of cons
Slide 12: Conclusions
> Ganaxolone IV 140 pg/kg/hr demonstrated rapid onset of antidepressant action * Clinically meaningful improvement of 5.6 and 4.2 HAM-D17 points over placebo at 48 hrs and 60 hrs, respectively. » GNX was safe and well-tolerated * No SAEs or discontinuations due to TRAEs * No syncope or loss of consc
Slide 13: Thank You
Thank You
Marinus Pharmaceuticals — Technical Presentation (December 2018) on 6ix